Journal: The Journal of clinical endocrinology and metabolism

Article Title: Placental sonic hedgehog pathway regulates foetal growth via insulin-like growth factor axis in preeclampsia.

doi: 10.1210/jc.2019-00335

Figure Lengend Snippet: Figure 3. SHH pathway and trophoblast syncytialization. (A) Downregulation of the SHH pathway in primary CTBs. Cyclopamine decreased the expression of PTCH1 (left) and GLI2 (middle) at mRNA (n 5 6) and protein levels (n 5 3, right). (B) Cyclopamine-induced alteration of syncytium markers (n 5 6). (C) Fluorescent immunocytochemistry of CTBs treated with rSHH (200 ng/mL, 48 h, n 5 4) and cyclopamine (5 mM, 48 h, n 5 4). Data are presented as mean 6 SEM. Scale bars, 50mm. Representative images are shown in (C).

Article Snippet: Cyclopamine (5 mM, catalog no. sc-200929, Santa Cruz Biotechnology), an SMO inhibitor, and/or recombinant SHH (rSHH) protein (200 ng/mL, catalog no. 1314-SH, R&D Systems, Minneapolis, MN) were used to examine the potential roles of the SHH pathway in placental development.

Techniques: Expressing, Immunocytochemistry

Journal: The Journal of clinical endocrinology and metabolism

Article Title: Placental sonic hedgehog pathway regulates foetal growth via insulin-like growth factor axis in preeclampsia.

doi: 10.1210/jc.2019-00335

Figure Lengend Snippet: Figure 5. Noncanonical SHH pathway and trophoblast syncytialization. (A) mRNA expressions of syncytium markers and b-hCG protein levels in primary CTBs treated with forskolin, an ADCY activator (20 mM, n 5 6). (B) Western blot analysis of CREB phosphorylation in CTBs treated with forskolin (20 mM, n 5 3), rSHH (200 ng/mL, n 5 3), and cyclopamine (5 mM, n 5 3). (C) Expressions of ADCY family in CTBs treated with cyclopamine (5 mM, 48 h, n 5 6). (D) Fluorescent immunocytochemistry of CTBs treated with forskolin (20 mM, 48 h, n 5 4). Data are presented as mean 6SEM. Scale bars, 50mm. Representative images are shown in (B) and (D). *P , 0.05, **P , 0.01, ***P , 0.001. NS, not significant.

Article Snippet: Cyclopamine (5 mM, catalog no. sc-200929, Santa Cruz Biotechnology), an SMO inhibitor, and/or recombinant SHH (rSHH) protein (200 ng/mL, catalog no. 1314-SH, R&D Systems, Minneapolis, MN) were used to examine the potential roles of the SHH pathway in placental development.

Techniques: Western Blot, Phospho-proteomics, Immunocytochemistry

Journal: The Journal of clinical endocrinology and metabolism

Article Title: Placental sonic hedgehog pathway regulates foetal growth via insulin-like growth factor axis in preeclampsia.

doi: 10.1210/jc.2019-00335

Figure Lengend Snippet: Figure 6. Canonical and noncanonical SHH pathway in regulation of the placental IGF1R pathway. (A) Close correlation between the SHH pathway and the IGF axis in control and preeclampsia placentas (n 5 10 in each group). (B–D) Expressions of major components of the IGF axis in CTBs treated with (B) forskolin (20 mM, 24 h, n 5 5), (C) cyclopamine (5 mM, 24 h, n 5 6), and (D) GLI2 siRNAs (48 h, n 5 6). (E) Western blot analysis of IGF1R expression in CTBs (48 h, n 5 3) treated with forskolin (20 mM), cyclopamine (5 mM), GLI2 siRNAs, rSHH (200 ng/mL), and SQ22536 (100 mM). (F) Pathway analysis of microarray data demonstrating that the SHH pathway was closely associated with ADCY activation pathway, CREB phosphorylation pathway, and IGF1R pathway. (G) Schema of the SHH pathway that regulates the IGF1R pathway in the placenta. Data are presented as mean 6 SEM. Representative images are shown in (E). NS, not significant.

Article Snippet: Cyclopamine (5 mM, catalog no. sc-200929, Santa Cruz Biotechnology), an SMO inhibitor, and/or recombinant SHH (rSHH) protein (200 ng/mL, catalog no. 1314-SH, R&D Systems, Minneapolis, MN) were used to examine the potential roles of the SHH pathway in placental development.

Techniques: Control, Western Blot, Expressing, Microarray, Activation Assay, Phospho-proteomics

Journal: eBioMedicine

Article Title: Leukemia inhibitory factor is a therapeutic target for renal interstitial fibrosis

doi: 10.1016/j.ebiom.2022.104312

Figure Lengend Snippet: Primers used in this study.

Article Snippet: When 60% confluence was reached, cells were switched to serum-free medium for 12 h and treated with TGF-β1 (240-b-002, R&D, Minneapolis, MN, USA), TNF-α (T66674, Sigma–Aldrich, St. Louis, MO, USA), AngII (GF165, Sigma–Aldrich, St. Louis, MO, USA), SHH (HZ-1306, ProteinTech Group, Chicago, IL, USA), OSM (HY-P7052, MedChemExpress, NJ, USA), IL-11 (218-IL-005, R&D, Minneapolis, MN, USA) or LIF (7734-LF-025, R&D, Minneapolis, MN, USA) in the serum-free medium for indicated time period.

Techniques: Sequencing

Journal: Pharmaceutics

Article Title: Curcumin Disrupts a Positive Feedback Loop between ADMSCs and Cancer Cells in the Breast Tumor Microenvironment via the CXCL12/CXCR4 Axis

doi: 10.3390/pharmaceutics15112627

Figure Lengend Snippet: Curcumin inhibited the NF-κB signaling pathway and SHH expression, which are downstream of the CXCL12/CXCR4 axis in ADMSCs. ( A , B ) Relative pNF-κB translocation levels in nuclei of ADMSCs after treatment for 4 h were imaged via immunofluorescence staining and quantified. The protein levels of ( C ) pNF-κB, NF-κB, and ( D ) SHH were determined using Western blotting analysis. ( E ) The secretion level of SHH was quantified using ELISA kits. * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the control group; # p < 0.05, ## p < 0.01, and ### p < 0.001 compared to the CAF group; Con: control; CAF: MCF7-CM-treated group; AMD: MCF7-CM-treated group with 20 μM of AMD3100; Cur: MCF7-CM-treated group with 20 μM of curcumin; scale bar: 100 μm.

Article Snippet: The SHH protein in the samples was quantified using the Human SHH (Sonic Hedgehog Protein) ELISA Kit (Elabscience, Houston, TX, USA), according to the manufacturer’s instructions.

Techniques: Expressing, Translocation Assay, Immunofluorescence, Staining, Western Blot, Enzyme-linked Immunosorbent Assay, Control